Statement re share price, update on EpiSwitch PSE
Oxford BioDynamics Plc has issued a statement addressing recent share price movements, clarifying that the UK National Screening Committee's draft recommendation on prostate cancer screening has no direct impact on the company or its EpiSwitch PSE test. The company highlighted that sales of its PSE test in the US and to private healthcare in the UK have shown consistent growth, with six consecutive record months reported from June to November 2025, indicating ongoing commercial success.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
The Board of Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, notes the recent movement in the Company's share price following the publication on 28 November of the UK National Screening Committee's (NSC) draft recommendation in respect of prostate cancer screening.
The NSC's draft recommendation has no direct impact on OBD or the Group's EpiSwitch PSE test. PSE test sales in the US and to private healthcare in the UK have continued to increase, with six successive record months reported from June to November 2025.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.